- Sputnik International
World
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

WHO Advises Against Use of Gilead's Remdesivir as Coronavirus Treatment

© REUTERS / Mike BlakeGilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020.
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. - Sputnik International
Subscribe
Remdesivir is an antiviral medication developed by biopharmaceutical company Gilead Sciences. The drug is approved in some countries for the treatment of COVID-19. In October, Remdesivir became the first coronavirus treatment approved in the US by the Food and Drug Administration (FDA).

On Thursday, the World Health Organization (WHO) advised doctors against using Remdesivir as a treatment for COVID-19 patients, saying that there is "no evidence" that the drug shortens recovery time.

The recommendations were published by the WHO Guideline Development Group, which provides advice based on the most recent data, in the British medical trade journal The BMJ. 

“After thoroughly reviewing this evidence, the WHO GDG expert panel, which includes experts from around the world including four patients who have had covid-19, concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement,” the group wrote in a press release.

The WHO recommendations were based on results of four international drug trials involving over 7,000 patients infected with the coronavirus disease.

In response, Gilead stated that the drug was recognized by some health institutes in the US, as well as several expert communities in Japan, the UK and Germany.

“We are disappointed the WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with COVID-19 in approximately 50 countries,” Gilead spokesman Chris Ridley said in a statement cited by CNBC.

Under the brand name Veklury, the drug is administered intravenously, and is recommended to be used only in clinical settings comparable to hospital inpatient care.

The FDA officially approved the use of remdesivir in October, making it the first approved COVID-19 treatment in the US. Gilead referred to this approval as a "milestone" that indicated a "shared commitment" to help speed the healing of those infected by the novel coronavirus.

© AP Photo / Alex BrandonPresident Donald Trump removes his mask as he stands on the Blue Room Balcony upon returning to the White House Monday, Oct. 5, 2020, in Washington, after leaving Walter Reed National Military Medical Center, in Bethesda, Md. Trump announced he tested positive for COVID-19 on Oct. 2
WHO Advises Against Use of Gilead's Remdesivir as Coronavirus Treatment - Sputnik International
President Donald Trump removes his mask as he stands on the Blue Room Balcony upon returning to the White House Monday, Oct. 5, 2020, in Washington, after leaving Walter Reed National Military Medical Center, in Bethesda, Md. Trump announced he tested positive for COVID-19 on Oct. 2

Remdesivir came to the attention of the public earlier this year after being reported to have reduced recovery times for some patients infected with COVID-19. According to one doctor who treated US President Donald Trump, when the latter became infected with the disease, he was given the drug to shorten the time of his recovery.

The first vaccine against COVID-19, Sputnik V, registered in August in Russia and the world, is currently undergoing phase 3 trials in Russia, Belarus, Venezuela and the UAE. The vaccine is reported to have a 92-percent efficacy in preventing the infection, according to data from trial participants who have received both of the two vaccine injections.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала